1. Home
  2. CFBK vs SGMT Comparison

CFBK vs SGMT Comparison

Compare CFBK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Bankshares Inc.

CFBK

CF Bankshares Inc.

HOLD

Current Price

$33.68

Market Cap

178.1M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.99

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFBK
SGMT
Founded
1892
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
178.1M
169.4M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
CFBK
SGMT
Price
$33.68
$6.99
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$31.50
$26.13
AVG Volume (30 Days)
84.2K
1.3M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
1.23%
N/A
EPS Growth
30.58
N/A
EPS
0.77
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
$31.99
N/A
Revenue Next Year
$9.09
N/A
P/E Ratio
$42.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.10
$4.50
52 Week High
$34.34
$10.46

Technical Indicators

Market Signals
Indicator
CFBK
SGMT
Relative Strength Index (RSI) 68.57 47.42
Support Level $28.40 $7.04
Resistance Level $33.97 $7.39
Average True Range (ATR) 0.83 0.44
MACD -0.00 -0.08
Stochastic Oscillator 87.17 21.77

Price Performance

Historical Comparison
CFBK
SGMT

About CFBK CF Bankshares Inc.

CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: